Enhancing diabetic foot wound healing with topical macrophage-regulating cream (ON101): a case series.

A number of treatments have been developed to treat hard-to-heal (chronic) diabetic foot ulcers (DFUs). This case series the use of ON101-a new topical macrophage regulatory cream for the treatment of DFUs, that helped achieve limb-salvage outcomes with an adequate safety profile. Patients with hard-to-heal DFUs-primarily on the toes and plantar surfaces-were enrolled in the study. After infection control, wound debridement or angioplasty intervention, ON101, containing 1.25% extracts of Plectranthus amboinicus (0.25%) and Centella asiatica (1%), was applied topically to the wounds up to twice daily. The condition of the wounds, complications, healing progression and other details were documented. In total, 10 patients, with a mean age of 59.2 years (range: 35-77 years), were included in the study following surgical debridement, sequestrectomy or revascularisation. Wound sizes ranged from 1-66 cm2. After receiving ON101 treatment for durations ranging from 14-264 days, most wounds healed without complications, except for one patient with osteomyelitis who did not fully recover. All patients expressed satisfaction with the outcomes and had no reported complications at the six-month follow-up. This case series demonstrated the real-world outcomes of ON101, which exhibited good healing efficacy in the treatment of DFUs, making it a promising strategy for the topical treatment of these ulcers.